
An overview of what’s next, in terms of the use of various frontline treatment regimens, that include novel agents to manage patients with newly diagnosed multiple myeloma.
Your AI-Trained Oncology Knowledge Connection!
An overview of what’s next, in terms of the use of various frontline treatment regimens, that include novel agents to manage patients with newly diagnosed multiple myeloma.
Recommendations regarding best approaches to using novel therapies to treat multiple myeloma based on current drug approvals as well as new therapies in the pipeline.
Treatment options available for an elderly man with multiple myeloma upon first relapse.
What needs to be investigated further before adopting MRD assessments for multiple myeloma into routine clinical practice.
Considerations for selecting between a conventional front-line triplet regimen to manage a patient with high-risk multiple myeloma who is ineligible for transplant vs a new quadruplet regimen, as demonstrated in recent clinical trial data.
Various considerations affect choice of first-line therapy for a patient with newly diagnosed multiple myeloma who is ineligible for transplant.
An overview of treatment regimens available for patients with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation.
The current rationale for managing a patient with newly diagnosed multiple myeloma with consolidation therapy post-transplant.
Published: February 1st 2022 | Updated: